Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Hansoh Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials for its new antibody-drug conjugate, HS-20110, aimed at treating advanced solid tumors. This development marks a significant step in the company’s innovation efforts, potentially impacting its market position.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.